Form 4: Recursion Pharmaceuticals COO Tina Marriott Executes Stock Option and Sells Shares Under 10b5-1 Plan

Tina Marriott, President and COO of Recursion Pharmaceuticals, executed a stock option and sold 6,000 shares of Class A Common Stock at an average price of $6.3091, according to a recent SEC filing.

Summary

• Tina Marriott, the President and COO of Recursion Pharmaceuticals, executed a stock option to purchase 6,000 shares of Class A Common Stock at $1.06 per share on October 24, 2024.
• Simultaneously, Marriott sold 6,000 shares of Class A Common Stock at an average price of $6.3091 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on March 1, 2024.
• Following these transactions, Marriott directly owns 521,138 shares of Class A Common Stock.
• Marriott also holds options to purchase a total of 1,243,049 shares at various exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company executives. It is common for executives to utilize 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options as a significant component.
• The vesting schedules and exercise prices of these options are typically structured to align executive incentives with long-term shareholder value creation.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their personal finances while complying with insider trading regulations.
• Comparable companies such as Exscientia, Schrödinger, and Relay Therapeutics also have executives who regularly file Form 4s related to stock option exercises and sales.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-defined trading plan.
• The sale of shares by an executive could be perceived negatively if not understood in the context of the 10b5-1 plan.

Key Dates